EdiGene and Arbor Biotechnologies Partnered to Advance Programs for Ex Vivo Engineered Cell Therapy

EdiGene, a biotechnology company that is focused on the translation of the gene-editing technologies into the transformative therapies for the patients suffering from cancer and different genetic disorders has partnered with Arbor Biotechnologies, a biotechnology company developing and discovering the next generation of the genetic medicines for the purpose of accessing the proprietary CRISPR gene editing technology of Arbor biotechnology for the certain ex vivo engineered cell therapy in the field of the oncology.

Devyn Smith, chief executive officer of Arbor Biotechnology said, by partnering with the leading developers of the engineered cell therapy has been a key component of the strategy of the Arbor Biotechnology for the purpose of broadening the potential of the company’s CRISPR discovery engine beyond the fully owned vivo genetic medicine approaches for the benefit of the more number of the patients.

He also said that, they are also looking forward for the expansion of the global impact of the proprietary gene editing technologies of Arbor Biotechnology through their partnership with the EdiGene, and the licensed technology has been a part of the proprietary CRISPR gene-editing portfolio of the Arbor biotechnology that has been tailored for addressing the underlying pathology of the various genetic diseases.

Dong Wei, chief executive officer of EdiGene said that, it has been great for working with the team of Arbor Biotechnology in the previous two years for the purpose of optimizing the ways of integration of ex vivo platforms and proprietary CRISPR system of Arbor Biotechnology.